|

CAR-T Cell Therapy Clinical Trials

7 actively recruiting trials across 2 locations

Also known as: Axicabtagene ciloleucel, Chimeric Antigen Receptor T-cell, Chimeric antigen receptor T-Cell Therapy, Lisocabtagene maraleucel .

Pipeline

Phase 1: 4Phase 2: 2

Top Sponsors

National University Hospital, Singapore2
Washington University School of Medicine1
University Hospital, Lille1
The First Affiliated Hospital of Soochow University1
Lazaros Lekakis1

Indications

Cancer7
CAR T-Cell-Related Encephalopathy Syndrome2
Lymphoblastic Leukemia, Acute, Childhood2
CAR2
Lymphoblastic Leukemia, Acute Adult2

Other5 trials

ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.

Phase 1

CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

Phase 1

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Phase 2

Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19

Phase 1

Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment

Miami, Florida1 trial

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

University of Miami

Phase 2

St Louis, Missouri1 trial

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.